现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • Firibastat
Firibastat的可视化放大

Firibastat

Firibastat (QGC001) 是一种口服活性的 EC33 前体药物。Firibastat 是一种首创的脑氨基肽酶 A (APA) 抑制剂 (Ki=200 nM),选择性和特异性地抑制高血压大鼠脑血管紧张素 II 转化为血管紧张素 III,并降低血压。

原价
¥1300-9712
价格
1040-7770
Firibastat的二维码

所有产品仅用于科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

  • 库存: 现货
可选包装 >>>
首页
  • 货号: ajcx33078
  • CAS: 648927-86-0
  • 别名: QGC001; RB150
  • 分子式: C8H20N2O6S4
  • 分子量: 368.51
  • 纯度: >98%
  • 溶解度: Water : 41.67 mg/mL (113.08 mM; ultrasonic and warming and heat to 60°C)
  • 储存: Store at -20°C
  • 库存: 现货

Background

Firibastat (QGC001), an orally active brain penetrating prodrug of EC33, is a first-in-class brain aminopeptidase A (APA) inhibitor (Ki=200 nM). Firibastat selectively and specifically inhibits conversion of brain angiotensin-II into angiotensin-III and decreases blood pressure in hypertensive rats[1][2].


When given orally, Firibastat (0.1-30 mg/kg; p.o.) crosses the gastrointestinal and blood-brain barriers, enters the brain, and generates two active molecules of EC33 which inhibit brain APA activity, blocking brain angiotensin III formation, and decrease blood pressure for several hours in hypertensive rats[2].


[1]. Ferdinand KC, et al. Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins. Circulation. 2019;140(2):138-146.
[2]. Keck M, et al. Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions. Curr Hypertens Rep. 2019;21(7):50. Published 2019 May 21.

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服